Table 2.
Therapeutic Compound | Therapeutic Strategy | Therapeutic Mechanism |
---|---|---|
Kinetin | PINK1 activator | Direct binding to the active site |
Celastrol | PINK1 activator | Enhancing expression |
Salidroside | PINK1 activator | Enhancing expression |
No name | Parkin activator | Direct binding to the active site |
USP30i | USP30 inhibitor | Direct binding to the active site |